Salmon Calcitonin

ApprovedSmall molecule

Novartis

Salmon Calcitonin is one of 91 small molecule programs targeting Osteoarthritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoporosisActive, not recruiting

FibromyalgiaActive, not recruiting

X-Linked HypophosphatemiaActive, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

OsteoporosisPhase 3

Active, not recruiting

FibromyalgiaApproved

Active, not recruiting

X-Linked HypophosphatemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Salmon Calcitonin

Novartis

Approved

3 2

Ilaris

Novartis

Preclinical

2 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 5

Catapres

Boehringer Ingelheim

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Paracetamol

GSK

Preclinical

4 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Benadryl

PParkedale

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Women3 trials

Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women

Completed·RRene Rizzoli·Phase 3·NCT00372099·90 enrolled

Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women

Completed· Novartis logo

Novartis·Phase 4·NCT00239889·300 enrolled

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Completed· Novartis logo

Novartis·Phase 1·NCT00411125·86 enrolled

Osteoarthritis3 trials

Effects of Oral Salmon Calcitonin in Human Osteoarthritis

Terminated·UUniversité Catholique de Louvain·Phase 2·NCT00376311·54 enrolled

SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Completed·NNordic Bioscience A/S·Phase 1·NCT00486369

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Terminated·NNordic Bioscience A/S·Phase 3·NCT00704847·1,030 enrolled

Osteoporosis1 trial

A Study for Patients With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00414973·364 enrolled

Fibromyalgia1 trial

Calcitonin in the Treatment of Fibromyalgia

Withdrawn·UUnidad de Investigacion en Enfermedades Cronico-Degenerativas·Phase 4·NCT00754884

X-linked hypophosphatemia1 trial

Calcitonin for Treating X-linked Hypophosphatemia

Completed·YYale University·N/A·NCT01652573·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Salmon Calcitonin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Salmon Calcitonin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Salmon Calcitonin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Salmon Calcitonin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Women3 trials

Osteoarthritis3 trials

Osteoporosis1 trial

Fibromyalgia1 trial

X-linked hypophosphatemia1 trial

References

Drug Info

Quick Facts

Related News